BG
STML

BlackRock Group’s Stemline Therapeutics, Inc. STML Stock Holding History

BlackRock Group’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-17,793
Closed -$83K – 3064
2016
Q1 		$83K Hold
17,793
– – ﹤0.01% 2812
2015
Q4 		$112K Buy
+17,793
New +$144K ﹤0.01% 2661
2014
Q2 		– Sell
-2,043
Closed -$42K – 2892
2014
Q1 		$42K Buy
+2,043
New +$49.6K ﹤0.01% 2669

Other funds holding STML

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Group's STML Position: Q2 2016 in Review

BlackRock Group sold out of Stemline Therapeutics, Inc. (STML) in Q2 2016, closing a stake of 17,793 shares — an estimated $83K sold.

BlackRock Group first reported a position in STML in Q1 2014 and held it in 3 quarters. The position peaked at $112K in Q4 2015. 61 funds tracked by Wall St. Rank hold STML as of Q2 2016.

  • BlackRock Group reported no remaining Stemline Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
  • BlackRock Group sold 17,793 Stemline Therapeutics, Inc. shares in Q2 2016, an estimated $83K.
  • BlackRock Group first reported a position in Stemline Therapeutics, Inc. in Q1 2014 and held it in 3 quarters.
  • BlackRock Group's Stemline Therapeutics, Inc. position peaked at $112K in Q4 2015.
  • 61 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2016.

Based on BlackRock Group's 13F filing for Q2 2016, filed 10 Aug 2016.